Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026)
Prothena Corp Public (PRTA) posted quarterly Cash from Restructuring of $480000.0 for Q1 2026, up 111.13% quarter-over-quarter from -$4.3 million in Q4 2025.
Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026) Analysis & Trends
Prothena Corp Public's Cash from Restructuring history runs 4 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- In Q1 2026, Cash from Restructuring changed N/A year-over-year to $480000.0; the TTM figure through Mar 2026 stood at $13.8 million (changed N/A YoY), while the FY2025 annual figure was $13.3 million, changed N/A from the prior year.
- Cash from Restructuring for Q1 2026 stood at $480000.0, up from -$4.3 million in the prior quarter.
- The five-year high for Cash from Restructuring was $30.3 million in Q2 2025, with the low at -$12.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.49 Mn |
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | -4.31 Mn |
| Sep 30, 2025 | -12.72 Mn |
| Jun 30, 2025 | 30.33 Mn |
| Mar 31, 2019 | -461,000.00 |
| Dec 31, 2018 | -3.88 Mn |
| Sep 30, 2018 | -11.54 Mn |
| Jun 30, 2018 | 15.88 Mn |